Deutsche Bank
ALNY icon

Deutsche Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Deutsche Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,200
Closed -$753K – 3593
2024
Q4 		$753K Buy
+3,200
New +$842K ﹤0.01% 2396
2024
Q3 		– Sell
-50,200
Closed -$12.2M – 3605
2024
Q2 		$12.2M Buy
50,200
+33,200
+195% +$5.24M 0.01% 944
2024
Q1 		$2.54M Sell
17,000
-800
-4% -$133K ﹤0.01% 1549
2023
Q4 		$3.41M Buy
+17,800
New +$3.03M ﹤0.01% 1415
2023
Q2 		– Sell
-50
Closed -$10K – 3806
2023
Q1 		$10K Buy
+50
New +$10.5K ﹤0.01% 3784
2017
Q2 		– Sell
-630
Closed -$32K – 4913
2017
Q1 		$32K Buy
+630
New +$29.1K ﹤0.01% 4356
2015
Q1 		– Sell
-80
Closed -$7K – 5097
2014
Q4 		$7K Buy
+80
New +$7.41K ﹤0.01% 5789
2014
Q3 		– Sell
-575
Closed -$36K – 5870
2014
Q2 		$36K Sell
575
-625
-52% -$37.1K ﹤0.01% 5078
2014
Q1 		$6K Buy
1,200
+300
+33% +$23.2K ﹤0.01% 5132
2013
Q4 		$12K Buy
+900
New +$53.7K ﹤0.01% 4849
2013
Q3 		– Sell
-500
Closed -$2K – 5516
2013
Q2 		$2K Buy
+500
New +$13.3K ﹤0.01% 5148

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's ALNY Position: Q2 2026 in Review

Deutsche Bank increased its Alnylam Pharmaceuticals (ALNY) stake by 7.1% in Q2 2026, buying an estimated $16.3M and bringing the position to 815,400 shares worth $245M. The position accounts for 0.07% of the portfolio, ranked #244.

Deutsche Bank first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $283M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Deutsche Bank held 815,400 shares of Alnylam Pharmaceuticals worth $245M as of Q2 2026.
  • Deutsche Bank bought 53,936 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $16.3M.
  • Alnylam Pharmaceuticals made up 0.07% of Deutsche Bank's portfolio in Q2 2026, its #244 holding.
  • Deutsche Bank first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Deutsche Bank's Alnylam Pharmaceuticals position peaked at $283M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.